Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 121,474 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Alcohol-Related Disorders, Alcohol Drinking, Alcoholism, Alcohol Abuse, Alcohol Use Disorders
Interventions: Motivation Enhancement Therapy, Modified Behavioral Self-Control Therapy, Naltrexone, Brief Advice, Referral to specialty substance use disorder treatment; Behavioral · Drug · Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Great Neck, New York

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 40 Years to 90 Years · Male only
Enrollment: 2,033 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: In-person education, E-communication, Control; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Open Angle Glaucoma and Ocular Hypertension
Interventions: Ophthalmic Insert; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Schizophrenia
Interventions: Neuroadaptive cognitive training, Computer games; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 12 Years to 35 Years
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sensory Processing Disorder, Special Education, Autism
Interventions: Sensory diet; Other
Lead sponsor: Pingale, Vidya, OTR; Individual
Eligibility: 4 Years to 11 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cliffside Park, New Jersey

Conditions: Antisocial Behavior
Interventions: Multisystemic Therapy-Emerging Adults, Enhanced Treatment as Usual; Behavioral
Lead sponsor: Chestnut Health Systems; Other
Eligibility: 16 Years to 26 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 4
States / cities: Hamden, Connecticut • Hartford, Connecticut • New Haven, Connecticut + 1 more

Conditions: Colorectal Cancer, Lung Cancer, Breast Cancer, Head and Neck Cancer, Prostate Cancer
Interventions: GM-CT-01, 5-fluorouracil; Drug
Lead sponsor: Galectin Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 4
States / cities: Jacksonville, Florida • New Orleans, Louisiana • Ann Arbor, Michigan + 1 more

Conditions: Preeclampsia
Interventions: 2% buffered hypertonic saline administration; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Glaucoma, Open Angle
Interventions: brimonidine, timolol; Drug
Lead sponsor: Chicago Center for Vision Research; Other
Eligibility: 30 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 12
States / cities: Little Rock, Arkansas • Gainesville, Florida • Palm Beach Gardens, Florida + 7 more

Conditions: Healthy, Renal Impairment
Interventions: Enlicitide; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Edgewater, Florida • Hallandale, Florida • Inverness, Florida + 2 more

Conditions: Parkinson's Disease, Sleep Disordered Breathing, Sleep Obstructive Apnea
Interventions: Neurocognitive function, Sleep evaluations; Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acquired Immunodeficiency Syndrome, HIV Infection
Interventions: IL-2 plus Anti-TNF or Thalidomide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes Mellitus, Insulin Resistance
Interventions: Metformin, saxagliptin, AZD9668, placebo; Drug
Lead sponsor: Nick Giannoukakis, PhD; Other
Eligibility: 21 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Kidney Disease
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 2,682,052 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Minneota, Minnesota

Conditions: Prostate Cancer Metastatic
Interventions: ARV-110; Drug
Lead sponsor: Arvinas Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 54
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 51 more

Conditions: Intermittent Claudication
Interventions: K-134, Cilostazol 100 mg BID, Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 30
States / cities: Tucson, Arizona • Little Rock, Arkansas • Beverly Hills, California + 27 more

Conditions: Healthy
Interventions: Visual stimuli; Behavioral
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Candidiasis
Interventions: Anidulafungin, VER002; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: King of Prussia, Pennsylvania

Conditions: Seasonal Allergic Rhinitis, SAR
Interventions: BDP HFA, Placebo nasal aerosol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 715 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 45
States / cities: Oxford, Alabama • Bell, California • Costa Mesa, California + 40 more

Conditions: Diabetic Neuropathy, Painful
Interventions: AGN 203818, placebo capsule; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Atypical Squamous Cells of Undetermined Significance, Cervical Cancer, High-grade Squamous Intraepithelial Lesion, Low-grade Squamous Intraepithelial Lesion
Interventions: HspE7, placebo, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Orange, California

Conditions: Human Immunodeficiency Virus (HIV) Infection
Interventions: Etravirine; Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 9
States / cities: Phoenix, Arizona • Beverly Hills, California • North Hollywood, California + 6 more

Conditions: Choreatic Disorder
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home

An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males

Diet and Physical Activity Changes Among Latina Breast Cancer Survivors

A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert

Effectiveness of Neuroadaptive Cognitive Training in Adolescents at Risk for Psychosis

Effects of Sensory Diets on Children's Sensory Processing Skills, Psychosocial Skills, and Classroom Engagement

Multisystemic Therapy-Emerging Adults (MST-EA) for Substance Abuse

Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors

Hypertonic Saline Use in Preeclampsia

Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma

A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)

Sleep Disordered Breathing and Its Impact on Neuro-cognitive Performance and Quality of Life in Parkinson Disease

Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

OPTIMISE-CKD Drug Utilization

Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication

Human Perception on Medical Extended Reality Devices

The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy

SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients

Heart and Skeletal Muscle Problems in Neuroacanthocytosis